Payment overview · 2025
General Payments
$2,913.98
96 reported records · 16 companies
Healthcare provider profile · identity verified
William Chung, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BROOKLYN, NY · NPI 1043809031
Verified facts
What the public records show
CMS Open Payments records show William Chung, FNP received $2,913.98 in general payments during 2025 across 96 reported records.
Gilead Sciences, Inc. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Prolia, Rybelsus, Vemlidy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $976.70 | 33.5% | 20 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $594.50 | 20.4% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $257.11 | 8.8% | 8 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $177.79 | 6.1% | 12 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $177.47 | 6.1% | 12 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $151.14 | 5.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.08 | 4.0% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.68 | 3.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $91.76 | 3.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $74.04 | 2.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $60.51 | 2.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.44 | 1.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.95 | 1.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.52 | 0.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.71 | 0.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.58 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,913.98 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $575.75 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $257.11 | 8 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $206.84 | 10 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $177.79 | 12 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $177.47 | 12 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $151.14 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $74.04 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.35 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.35 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $46.44 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.33 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.33 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.33 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.95 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.95 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $36.73 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 42 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 25 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 25 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 473 | 142 |
| Simvastatin | Simvastatin | 425 | 118 |
| Vascepa | Icosapent Ethyl | 398 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 82 |
| Metformin Hcl | Metformin Hcl | 273 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 250 | 67 |
| Omeprazole | Omeprazole | 241 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 48 |
| Finasteride | Finasteride | 147 | 40 |
| Meclizine Hcl | Meclizine Hcl | 127 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 28 |
| Alendronate Sodium | Alendronate Sodium | 105 | 29 |
| Jardiance | Empagliflozin | 97 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 25 |
| Gabapentin | Gabapentin | 95 | 43 |
| Diclofenac Epolamine | Diclofenac Epolamine | 91 | 44 |
| Mometasone Furoate | Mometasone Furoate | 91 | 50 |
| Atenolol | Atenolol | 83 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 43 |
| Montelukast Sodium | Montelukast Sodium | 79 | 23 |
| Ammonium Lactate | Ammonium Lactate | 78 | 38 |
| Donepezil Hcl | Donepezil Hcl | 67 | 24 |
| Vemlidy | Tenofovir Alafenamide | 66 | 15 |
| Allopurinol | Allopurinol | 64 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 31 |
| Azithromycin | Azithromycin | 56 | 42 |
| Celecoxib | Celecoxib | 56 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 23 |
| Eliquis | Apixaban | 42 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 17 |
| Januvia | Sitagliptin Phosphate | 40 | 13 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 39 | 18 |
| Fluocinonide | Fluocinonide | 39 | 26 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | 14 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 31 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 30 | 18 |
| Linzess | Linaclotide | 29 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 17 |
| Amoxicillin | Amoxicillin | 27 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | 12 |
| Prolia | Denosumab | 25 | 20 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 21 |
| Loperamide | Loperamide Hcl | 23 | 16 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 22 | 14 |
| Hydrocortisone | Hydrocortisone | 22 | 11 |
| Procto-Med Hc | Hydrocortisone | 22 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | 17 |
| Lisinopril | Lisinopril | 20 | suppressed |
| Proctozone-Hc | Hydrocortisone | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Licart | Diclofenac Epolamine | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Viread | Tenofovir Disoproxil Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,913.98 · 96 records | Gilead Sciences, Inc. | ABRYSVO, ACCRUFER, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, GARDASIL 9, GEMTESA, IBSRELA, JARDIANCE, LINZESS, Livdelzi, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, VERQUVO, VOQUEZNA, Vemlidy, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error